via Neuroscience News
James Bibb, Ph.D., and colleagues have described a novel preclinical drug that could have the potential to combat depression, brain injury and diseases that impair cognition. The drug, which notably is brain-permeable, acts to inhibit the kinase enzyme Cdk5.
Cdk5 is a crucial regulator of signaling in brain neurons. Over three decades of study, it has been implicated in neuropsychiatric and neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease. Knocking out the enzyme in mice makes them resilient to stress, enhances their cognition, protects neurons from stroke and head trauma, and lessens neurodegeneration.
While inhibitors of Cdk5 could offer potential therapeutic benefits and new ways to study basic brain function, previous first- and second-generation anti-Cdk5 compounds largely get blocked at the blood-brain barrier that restricts movement of solutes from the blood to the central nervous system’s extracellular fluid. To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases.
Bibb and colleagues now report details of their anti-Cdk5, brain-permeable compound, 25-106. They also show that systemic administration of 25-106 alters neurobehavior in mice, reducing anxiety-like behavior.
“As perhaps the first robust systemic inhibitor, 25-106 represents an exciting and expandable and translatable pharmacological tool to study the function of Cdk5 activity in wild-type animals,” said Bibb, a professor in the University of Alabama at Birmingham Department of Surgery. “Achieving systemic applicability may be considered a step forward toward the testing of Cdk5 inhibitors to treat neuropsychiatric and neurodegenerative diseases. This provides a promising landscape for future studies to assess the effects of brain-permeable Cdk5 inhibitors to combat stress, anxiety, depression, addiction, cancer and neurodegeneration.”
The study, “Systemic administration of a brain permeable Cdk5 inhibitor alters neurobehavior,” is published in the journal Frontiers in Pharmacology.
In the paper, researchers describe synthesis of the aminopyrazole-based inhibitor, and they used molecular modeling to show that 25-106 appears to occupy the same hydrophobic binding pocket as the well-established Cdk5 inhibitor roscovitine.
They showed that 25-106 inhibited Cdk5 activity in a dose-dependent manner in brain striatal slices ex vivo, and that it also penetrated the brain after systemic administration in mice to inhibit Cdk5 in vivo. They measured the pharmacokinetic and pharmacodynamic parameters of 25-106 in blood plasma and the brains of mice, and the off-target distribution of 25-106 in the liver and kidneys.
Mice given systemic 25-106 showed modulated neurobehavior in the open field maze test and the tail suspension test, anxiolytic changes that have previously been linked to Cdk5 knockout mice.
They found that 25-106 is a non-selective inhibitor of both Cdk5 and another cyclin-dependent kinase, Cdk2, but note that very low levels of Cdk2 are found in the brain. However, any off-target or toxic effects of systemic inhibition of Cdk2 by 25-106 remain unknown.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Agricultural Microbial Global Market Report 2022: Rising Awareness About Organic Farming to Propel Growth - ResearchAndMarkets.com
The global agricultural microbial market is expected to grow from $4.25 billion in 2021 to $5.06 billion in 2022 at a compound annual growth rate (CAGR) of 19.2%. The agricultural microbial market is ...
- Clean Energy Reports 106.9 Million Gallons Delivered and Revenue of $97.2 Million for the Second Quarter of 2022
The Company delivered 106.9 million gallons in the second quarter ... 2021 was $0.00 and $25.6 million, respectively, which included $9.7 million in income from the AFTC. Non-GAAP income (loss ...
- Intercontinental Exchange Reports Strong Second Quarter 2022
Intercontinental Exchange (NYSE: ICE), a leading global provider of data, technology and market infrastructure, today reported financial results for the second quarter of 2022. For the quarter ended ...
- Silver Iodide Market Size to Grow by USD 106.72 million, Rising Demand for Cloud Seeding at Airports for Fog Dissipation to Drive Growth - Technavio
NEW YORK, Aug. 3, 2022 /PRNewswire/ -- Silver iodide is a fast ion conductor and an inorganic chemical compound that is highly ... is expected to grow by USD 106.72 million from 2021 to 2026.
- Best CBD Oils For Sleep: 10 Products To Help You Rest & Recover
Good sleep is so important for health. Sleep is when your body recovers from the day, and it’s also an opportunity for your mind to relax. Unfortunately, a lot of men struggle to get good rest. Stress ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- The Journal of biological chemistry
Adenine binding mode is a key factor in triggering the early release of NADH in coenzyme A-dependent methylmalonate semialdehyde dehydrogenase. A retroelement modifies pre-mRNA splicing: the ...
- Ex Vivo News and Research
The drug, which notably is brain-permeable, acts to inhibit the kinase enzyme Cdk5. In a recent study published in the journal Nature Communications, researchers developed a wireless theranostic ...
- Case Comprehensive Cancer Center
This approach has led to the discovery of novel inhibitors of the inflammatory disease kinase ... Abbott, D.W., Stearns, D.S., Letterio, J.J., and A.Y. Huang. (2016). Cdk5 Disruption Attenuates Tumor ...
- Exploration of Synthetic Lethal Interactions as Cancer Drug Targets
performed a siRNA screen to identify kinases that upon knockdown sensitize cells to a PARP inhibitor.  Among the four validated genes that upon knockdown enhance the sensitivity is CDK5 ...
- Chakraborti, Ayanabha, M.S., Ph.D.
Dr. Chakraborti is an instructor in the Division of Gastrointestinal Surgery at the UAB Department of Surgery. He also serves as the managing director of the UAB Behavioral Assessment Core. Dr.